JP2024542633A - がん治療用cdk4阻害剤 - Google Patents

がん治療用cdk4阻害剤 Download PDF

Info

Publication number
JP2024542633A
JP2024542633A JP2024532158A JP2024532158A JP2024542633A JP 2024542633 A JP2024542633 A JP 2024542633A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024542633 A JP2024542633 A JP 2024542633A
Authority
JP
Japan
Prior art keywords
cancer
subject
bid
therapeutically effective
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542633A5 (cg-RX-API-DMAC7.html
Inventor
タン リン タン
ヤン ジン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2024542633A publication Critical patent/JP2024542633A/ja
Publication of JP2024542633A5 publication Critical patent/JP2024542633A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024532158A 2021-12-02 2022-11-29 がん治療用cdk4阻害剤 Pending JP2024542633A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US63/285,320 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US63/382,346 2022-11-04
US202263383969P 2022-11-16 2022-11-16
US63/383,969 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024542633A true JP2024542633A (ja) 2024-11-15
JP2024542633A5 JP2024542633A5 (cg-RX-API-DMAC7.html) 2025-11-19

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532158A Pending JP2024542633A (ja) 2021-12-02 2022-11-29 がん治療用cdk4阻害剤

Country Status (10)

Country Link
US (1) US20250041298A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542633A (cg-RX-API-DMAC7.html)
KR (1) KR20240112931A (cg-RX-API-DMAC7.html)
AU (1) AU2022400308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3240993A1 (cg-RX-API-DMAC7.html)
IL (1) IL312650A (cg-RX-API-DMAC7.html)
MX (1) MX2024006678A (cg-RX-API-DMAC7.html)
TW (1) TWI922768B (cg-RX-API-DMAC7.html)
WO (1) WO2023100070A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2026133192A1 (en) * 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
PT4181920T (pt) * 2020-07-15 2025-11-04 Ctxt Pty Ltd Inibidor de kat6 e combinações para o tratamento do cancro da mama
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
MX2023003054A (es) * 2020-09-15 2023-04-05 Pfizer Formas solidas de un inhibidor de cdk4.
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth

Also Published As

Publication number Publication date
MX2024006678A (es) 2024-06-19
IL312650A (en) 2024-07-01
AU2022400308B2 (en) 2026-02-12
KR20240112931A (ko) 2024-07-19
EP4440576A1 (en) 2024-10-09
TWI922768B (zh) 2026-04-21
AU2022400308A1 (en) 2024-05-16
CA3240993A1 (en) 2023-06-08
TW202329970A (zh) 2023-08-01
WO2023100070A1 (en) 2023-06-08
US20250041298A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
CN108024541B (zh) 用于治疗癌症的方法
JP2024001009A (ja) Pi3k阻害剤であるgdc-0077による癌の治療方法
JP2022504388A (ja) Pi3kアルファ阻害剤およびメトホルミンを用いたがんの処置方法
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
JP7667132B2 (ja) Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
EP4247363A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2021227007A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
AU2017245302B2 (en) Pharmaceutical combinations
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
KR20210121188A (ko) 아나스트로졸과 조합된 cdk4/6 억제제를 함유하는 조성물의 종양 질환 치료용 약제의 제조에서의 용도
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
AU2024269592A1 (en) Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
AU2019255410B2 (en) Nazartinib for use in the treatment of CNS metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251111